Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

Omacetaxine mepesuccinate (Synribo(®)) is an inhibitor of protein synthesis indicated for the treatment of patients with chronic- or accelerated-phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors. Myelosuppression is the most common and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leuk Lymphoma
Auteurs principaux: Akard, Luke, Kantarjian, Hagop M., Nicolini, Franck E., Wetzler, Meir, Lipton, Jeffrey H., Baccarani, Michele, Khoury, H. Jean, Kurtin, Sandra, Li, Elizabeth, Munteanu, Mihaela, Cortes, Jorge
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552050/
https://ncbi.nlm.nih.gov/pubmed/26436949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1071486
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires